Press Releases
Immunomic Therapeutics Announces Expansion of IP Portfolio
Press ReleasesITI announced the issuance of a new United States Patent which extends ITI’s intellectual property portfolio covering their proprietary vectors, including ITI’s out-licensed investigational DNA vaccines. Specifically, U.S. Patent No. 9,499,589Read moreASTELLAS Announces FDA Fast Track Designation for ASP0892
Press ReleasesASTELLAS Announces FDA Fast Track Designation for ASP0892 DNA Vaccine for Mitigation of Severe Hypersensitivity Reactions Due to Peanut Allergy NEWS PROVIDED BY Astellas Pharma Inc. Dec 20, 2016, 08:00Read moreImmunomic Therapeutics’ Cancer Discovery Incubator Finalists Announced
Press ReleasesFebruary 02, 2017 06:45 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced the finalists for their Cancer Discovery Incubator Award: AlcamenaRead moreImmunomic Therapeutics Announces Scientific Advisory Board Additions
Press ReleasesJanuary 05, 2017 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, announces two additions to their Scientific Advisory Board. “We could notRead more- Highlights Press ReleasesTOKYO, Dec. 20, 2016 /PRNewswire/ -- Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, "Astellas") and Immunomic Therapeutics, Inc. (Founder & CEO: William Hearl, Ph.D., "Immunomic Therapeutics") today announced that theRead more
Immunomic Therapeutics Announces Board Addition
Press ReleasesDecember 14, 2016 07:00 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, announces that C. Eric Winzer, M.B.A., currently serving Immunomic as ChiefRead moreImmunomic Therapeutics Announces Expansion of IP Portfolio
Highlights Press ReleasesAnnounces Issuance of Patent Related to LAMP-Vax™ Technology November 22, 2016 08:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced theRead moreJohns Hopkins University & Immunomic Therapeutics, Inc. Tech Transfer Celebration
Press ReleasesJohns Hopkins University & Immunomic Therapeutics, Inc. Tech Transfer Celebration On Tues., Nov. 10, Johns Hopkins University and Immunomic Therapeutics, Inc. celebrated the success of the LAMP-Vax platform. The technologyRead more- Highlights Press Releases-Immunomic Therapeutics to receive upfront payment of $300 million plus 10 percent royalties from potential products for allergic diseases, including peanut allergy- -Immunomic Therapeutics to retain rights of LAMP-vax platformRead more
Immunomic Therapeutics, Inc. to Present at Skin Vaccination Summit in Switzerland
Press ReleasesHERSHEY, Pa. and ROCKVILLE, Md., Aug. 28, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces thatRead moreImmunomic Therapeutics, Inc. Taps Micronaut to Visually Demonstrate Its LAMP-vax Programs
Press ReleasesHERSHEY, Pa. and ROCKVILLE, Md., June 16, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces thatRead moreImmunomic Therapeutics, Inc. CEO, William Hearl, Ph.D. to Speak at 2015 BIO International Convention
Press ReleasesHERSHEY, Pa. and ROCKVILLE, Md., June 3, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc. ("ITI"), a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces thatRead more